摘要
目的:观察中药组方对桥本甲状腺炎甲状腺自身抗体,辅助性(CD4+)T细胞,血清白细胞介素-12(IL-12),肿瘤坏死因子-α(TNF-α)表达的影响以及甲状腺的病理变化,以探讨可能的作用机制。方法:70例桥本甲状腺炎随机分为治疗组和非治疗组各35例。治疗组用中药组方,每日1剂,12周为1个疗程,非治疗组给予优甲乐口服。游离三碘甲腺原氨酸(FT3),游离甲状腺素(FT4),促甲状腺激素(TSH)治疗前后各检测1次;甲状腺免疫标志物的测定:CD4+T细胞,血清甲状腺球蛋白抗体(TGAb),过氧化物酶抗体(TPOAb),IL-12,TNF-α治疗前后各检测1次;甲状腺粗针穿刺病理检查治疗前后各检测1次。结果:两组患者治疗前后甲状腺功能比较无统计学意义,且治疗组患者治疗前后FT3,FT4,TSH无显著变化,说明中药对甲状腺激素水平无明显影响。两组患者治疗前TGAb,TPOAb,IL-12,TNF-α比较无统计学差异,治疗组治疗后CD4+TC,TGAb,TPOAb,IL-12,TNF-α水平较治疗前及非治疗组明显降低,显示本组药物能很好调节免疫,减轻甲状腺的体液免疫损伤,促进组织修复。结论:本组药物能很好调节免疫,减轻甲状腺的体液免疫损伤,促进组织修复,对桥本甲状腺炎的甲状腺组织具有保护和修复作用。
Objective： To investigate the potential action mechanism and observe the effects of traditional Chinese medicine compound（ TCMC） on the expressions of anti-thyroid autoantibodies of Hashimoto＇s thyroiditis,cluster differentiation antigen 4（ CD4＋） T lymphocytes,serum interleukin-12（ IL-12） and tumor necrosis factor-α（ TNF-α）, as well as the pathological changes of thyroid. Method： Seventy patients with Hashimoto＇s thyroiditis were randomly divided into two groups on average（ no significant difference in sex,age and disease course） ： treatment group and non-treatment group. The patients in treatment group were treated with TCMC（ one dose / day and 12 weeks / course）,while the patients in non-treatment group were treated with Euthyrox by oral administration. Before and after treatment,free triiodothyronine（ FT3）,free（ unbound） thyroxin（ e）（ FT4） and thyroid stimulating hormone（ TSH） were tested once respectively. CD4＋TC,thyroid globulin antibody（ TGAb）,thyroid peroxidase antibody（ TPOAb）,IL-12 and TNF-α as thyroid immunological markers were also tested once respectively before and after treatment; coarse needle biopsy（ CNB） was also done once respectively before and after treatment. Result： There was no statistically significant difference in thyroid function between two groups of patients before and after treatment, and there was no significant change in FT3,TSH,and FT4 in treatment group before and after treatment,indicating that Chinese medicine had no significant effect on thyroid hormone levels. Before treatment, there was no statistical difference in TGAb, TPOAb, IL-12, and TNF-αbetween two groups. CD4＋TC,TGAb,TPOAb,IL-12,TNF-α levels after treatment in treatment group were significantly lower than those before treatment and those in non-treatment group,indicating that this drug can well regulate immunity,reduce thyroid humoral immune damage,and promote tissue repair. Conclusion： This TCMC could mediate body immunity well,relieve the thyroid humoral immunity injury and accelerate the tissue repair,demonstrating protective and repairable function for the thyroid tissues of Hashimoto＇s thyroiditis.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2016年第7期191-194,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
山东省教育厅科研课题项目(J13LL59)
